BACKGROUND: Data from randomized trials on the development of anaemia after interruption of therapy are not well-described. METHODS: A total of 2,248 patients from the SMART study were included. We used Cox proportional hazards models to investigate development of new (≤12 mg/dl for females and ≤14 mg/dl for males) or worsening (≤8 mg/dl if anaemic at randomization) anaemia and Poisson regression analyses to explore the relationship between anaemia and the development of AIDS, death or non-AIDS events. RESULTS: Overall, 759 patients developed new or worsening anaemia: 420/1,106 (38.0%) in the drug conservation (DC) arm and 339/1127 (30.1%) in the viral suppression (VS) arm (P<0.0001). At 4 months after randomization, patients in the DC arm had a significantly increased risk of developing new or worsening anaemia (adjusted relative hazard 1.56, 95% CI 1.28-1.89). Currently anaemic patients had an increased incidence of AIDS (adjusted incidence rate ratio [IRR] 2.31, 95% CI 1.34-3.98), death (adjusted IRR 2.19, 95% CI 1.23-3.87) and non-AIDS events (adjusted IRR 2.98, 95% CI 2.01-4.40) compared to non-anaemic patients. CONCLUSIONS: Patients who interrupted combination antiretroviral therapy had a higher risk of new or worsening anaemia. Anaemic patients had a higher incidence of AIDS, non-AIDS defining events or deaths, possibly due to deteriorating health and subclinical disease.
RCT Entities:
BACKGROUND: Data from randomized trials on the development of anaemia after interruption of therapy are not well-described. METHODS: A total of 2,248 patients from the SMART study were included. We used Cox proportional hazards models to investigate development of new (≤12 mg/dl for females and ≤14 mg/dl for males) or worsening (≤8 mg/dl if anaemic at randomization) anaemia and Poisson regression analyses to explore the relationship between anaemia and the development of AIDS, death or non-AIDS events. RESULTS: Overall, 759 patients developed new or worsening anaemia: 420/1,106 (38.0%) in the drug conservation (DC) arm and 339/1127 (30.1%) in the viral suppression (VS) arm (P<0.0001). At 4 months after randomization, patients in the DC arm had a significantly increased risk of developing new or worsening anaemia (adjusted relative hazard 1.56, 95% CI 1.28-1.89). Currently anaemic patients had an increased incidence of AIDS (adjusted incidence rate ratio [IRR] 2.31, 95% CI 1.34-3.98), death (adjusted IRR 2.19, 95% CI 1.23-3.87) and non-AIDS events (adjusted IRR 2.98, 95% CI 2.01-4.40) compared to non-anaemic patients. CONCLUSIONS:Patients who interrupted combination antiretroviral therapy had a higher risk of new or worsening anaemia. Anaemic patients had a higher incidence of AIDS, non-AIDS defining events or deaths, possibly due to deteriorating health and subclinical disease.
Authors: Colette J Smith; Christian H Olsen; Amanda Mocroft; Jean Paul Viard; Schlomo Staszewski; George Panos; Therese Staub; Anders Blaxhult; Norbert Vetter; Jens D Lundgren Journal: AIDS Date: 2008-01-02 Impact factor: 4.177
Authors: Amanda Mocroft; Bruno Ledergerber; Kai Zilmer; Ole Kirk; Bernard Hirschel; Jean-Paul Viard; Peter Reiss; Patrick Francioli; Adriano Lazzarin; Ladislav Machala; Andrew N Phillips; Jens D Lundgren Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Amit C Achhra; Janaki Amin; Caroline Sabin; Haitao Chu; David Dunn; Lewis H Kuller; Joseph A Kovacs; David A Cooper; Sean Emery; Matthew G Law Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: Asha R Kallianpur; Quan Wang; Peilin Jia; Todd Hulgan; Zhongming Zhao; Scott L Letendre; Ronald J Ellis; Robert K Heaton; Donald R Franklin; Jill Barnholtz-Sloan; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; J A McCutchan; Igor Grant Journal: J Infect Dis Date: 2015-12-21 Impact factor: 5.226
Authors: Álvaro H Borges; Jeffrey I Weitz; Gary Collins; Jason V Baker; Yves Lévy; Richard T Davey; Andrew N Phillips; James D Neaton; Jens D Lundgren; Steven G Deeks Journal: AIDS Date: 2014-07-31 Impact factor: 4.177
Authors: Dana Weissberg; Frank Mubiru; Andrew Kambugu; Jan Fehr; Agnes Kiragga; Amrei von Braun; Anna Baumann; Marisa Kaelin; Christine Sekaggya-Wiltshire; Moses Kamya; Barbara Castelnuovo Journal: PLoS One Date: 2018-11-01 Impact factor: 3.240
Authors: Barbara N Harding; Bridget M Whitney; Robin M Nance; Heidi M Crane; Greer Burkholder; Richard D Moore; W Christopher Mathews; Joseph J Eron; Peter W Hunt; Paul Volberding; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata; Susan R Heckbert; Joseph A C Delaney Journal: BMJ Open Date: 2020-03-19 Impact factor: 2.692